New real-world data shows GLP-1 receptor agonists do not increase acute pancreatitis risk in Type 2 diabetes patients and may actually improve outcomes.
Researchers analyzed data from more than 740,000 patients using the TriNetX Research Network. Over 20,000 patients receiving GLP-1 receptor agonists were compared with matched controls not taking these medications.
The study found no evidence that semaglutide, liraglutide, dulaglutide, and tirzepatide increased pancreatitis risk. A trend toward lower risk emerged, though not statistically significant.
For patients who developed acute pancreatitis, those on GLP-1 therapy had significantly better outcomes. They showed lower risks of severe complications including sepsis, acute kidney injury, shock, and mechanical ventilation needs.
Mortality rates were substantially lower among patients treated with GLP-1 receptor agonists compared to non-users. These findings address persistent safety concerns about this widely prescribed drug class.
The retrospective observational study cannot establish causality, but provides reassurance for clinical practice regarding medications like Ozempic, Wegovy, and Mounjaro.